Affimed (NASDAQ:AFMD) 주식

Affimed

Affimed NV is a clinical-stage biopharmaceutical company. The company is engaged in discovering and developing targeted cancer immunotherapies. Its product candidates are being developed in the field of immuno-oncology, which represents an approach to cancer treatment that seeks to harness the body's immune defenses to fight tumor cells. It is active in the discovery, pre-clinical and clinical development of antibodies based on its core technology. The Company generates revenues from the provision of research and development services to third parties based on both Group and third party owned intellectual property. Geographically, it derives a majority of revenue from the United States and also has a presence in and Germany.

Affimed NV

U.S. stocks traded slightly higher this morning, with the Nasdaq Composite gaining around 0.2% on Friday.
Following the market opening Friday, the Dow traded up 0.09% to 42,361.24 while the NASDAQ rose 0.20% to 19,150.28. The S&amp;P 500 also rose, gaining, 0.14% to 5,925.12.
Check This Out: <a href="https://www.benzinga.com/analyst-ratings/price-target/25/05/45464436/wall-streets-most-accurate-analysts-give-their-take-on-3-defensive-stocks-delivering-high-dividend-yields-4">Wall Street&#8217;s Most Accurate Analysts Give Their Take On 3 Defensive Stocks Delivering High-Dividend Yields</a>
Leading and Lagging Sectors Communication services shares jumped by 0.7% on Friday.
In trading on Friday, energy stocks fell by 0.8%.
Top Headline
The University of Michigan consumer sentiment for the US dipped to 50.8 in May compared to April's reading of 52.2 and down from market estimates of 53.4.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul class="wp-block-list">
<li>Affimed N.V. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AFMD#NASDAQ">AFMD</a>) shares shot up 390% to $0.4269. Affimed recently announced it received a Nasdaq delisting notice.</li>
<li>Shares of Inozyme Pharma, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INZY#NASDAQ">INZY</a>) got a boost, surging 177% to $3.94 after the company announced BioMarin will acquire the company for about $270 million.</li>
<li>TSS, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSSI#NASDAQ">TSSI</a>) shares were also up, gaining 74% to $15.36 after the company reported a year-over-year increase in first-quarter revenue results.</li>
</ul>
Equities Trading DOWN
<ul class="wp-block-list">
<li>Healthcare Triangle, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HCTI#NASDAQ">HCTI</a>) shares dropped 67% to $0.0124.</li>
<li>Shares of LogProstyle Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LGPS#NASDAQ">LGPS</a>) were down 52% to $1.30.</li>
<li>Zenvia Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZENV#NASDAQ">ZENV</a>) was down, falling 29% to $1.2988 following full year 2024 results.</li>
</ul>
Commodities In commodity news, oil traded up 0.4% to $61.85 while gold traded down 1.3% at $3,184.80.
Silver traded down 0.8% to $32.41 on Friday, while copper fell 1.1% to $4.6320.
Euro zone
European shares were higher today. The eurozone's STOXX 600 rose 0.2%, while Spain's IBEX 35 Index rose 0.8%. London's FTSE 100 gained 0.5%, Germany's DAX 40 rose 0.1% and France's CAC 40 gained 0.2% during the session.
Asia Pacific Markets
Asian markets closed lower on Friday, with Japan's Nikkei falling 0.005%, Hong Kong's Hang Seng Index declining 0.46%, China's Shanghai Composite Index falling 0.40% and India's BSE Sensex declining 0.24%.
Economics
<ul class="wp-block-list">
<li>The University of Michigan consumer sentiment for the US dipped to 50.8 in May compared to April's reading of 52.2 and down from market estimates of 53.4.</li>
<li>U.S. import prices rose by 0.1% month-over-month in April compared to a revised 0.4% decline in the previous month.</li>
<li>U.S. building permits declined by 4.7% to an annualized rate of 1.412 million in April, recording the lowest level in eleven months.</li>
<li>U.S. housing starts increased 1.6% month-over-month in April to an annual rate of 1.361 million.</li>
<li>U.S. export prices increased 0.1% month-over-month in April, versus market estimates of a 0.5% fall.</li>
</ul>
Now Read This: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/25/05/45466164/jim-cramer-prefers-autozone-over-rival-buy-the-one-thats-not-going-to-stock-split">Jim Cramer Prefers AutoZone Over Rival: &#8216;Buy The One That&#8217;s Not Going To Stock Split&#8217;</a> </li>
</ul>
Photo via Shutterstock

Earnings

Equities

News

Eurozone

Commodities

Intraday Update

Markets

Trading Ideas

AFMD

HCTI

INZY

LGPS

TSSI

ZENV

US Stocks Edge Higher; Consumer Sentiment Falls In May

HC Wainwright &amp; Co. analyst Swayampakula Ramakanth downgrades Affimed (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AFMD#NASDAQ">AFMD</a>) from Buy to Neutral.

Downgrades

Analyst Ratings

HC Wainwright & Co. Downgrades Affimed to Neutral

WIIM

AFMD stock has given up its prior loss. Affimed shares were trading lower after the company announced it received a Nasdaq delisting notice. Also, Wells Fargo downgraded the stock from Overweight to Equal-Weight and cut its price target from $11 to $0.1.

Affimed shares are trading lower after the company announced it received a Nasdaq delisting notice. Also, Wells Fargo downgraded the stock from Overweight to Equal-Weight and cut its price target from $11 to $0.1.

Affimed N.V. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AFMD#NASDAQ">AFMD</a>), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today that it has received a written notice from the staff of the Nasdaq Listing Qualifications Department (the "Staff") notifying the Company that, in accordance with Nasdaq Listing Rule 5101, 5110(b) and IM-5101-1, the trading of the Company's common shares will be suspended at the opening of business on May 20, 2025, and a Form 25 Notification of Delisting will be filed with the U.S. Securities Exchange Commission to delist the Company's securities from The Nasdaq Stock Market ("Nasdaq").

Affimed Receives Nasdaq Delisting Notice; Trading To Be Suspended May 20

Wells Fargo analyst Yanan Zhu downgrades Affimed (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AFMD#NASDAQ">AFMD</a>) from Overweight to Equal-Weight and lowers the price target from $11 to $0.1.

Price Target

Wells Fargo Downgrades Affimed to Equal-Weight, Lowers Price Target to $0.1

U.S. stocks traded mixed midway through trading, with the Dow Jones index falling around 200 points on Tuesday.
The Dow traded down 0.49% to 42,203.63 while the NASDAQ gained 1.74% to 19,033.50. The S&amp;P 500 also rose, gaining, 0.86% to 5,894.52.
Check This Out: <a href="https://www.benzinga.com/25/05/45373483/top-2-materials-stocks-that-may-keep-you-up-at-night-in-may">Top 2 Materials Stocks That May Keep You Up At Night In May</a>
Leading and Lagging Sectors Information technology shares jumped by 2.3% on Tuesday.
In trading on Tuesday, health care stocks fell by 2.5%.
Top Headline
Consumer prices in the U.S. eased faster than expected in April, with fresh tariffs introduced by President Donald Trump appearing not to have a swift and tangible impact on the cost of living.
The Consumer Price Index (CPI) was 2.3% higher compared to a year ago, the Bureau of Labor Statistics said Tuesday, compared to economists&#8217; expectations of 2.4% and the previous reading.
The monthly gain was 0.2%, rebounding from a prior decline of 0.1%, yet falling short of a 0.3% forecasted.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul class="wp-block-list">
<li>HCW Biologics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HCWB#NASDAQ">HCWB</a>) shares shot up 165% to $14.01 after the company announced it presented studies on HCW9206.</li>
<li>Shares of Microvast Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MVST#NASDAQ">MVST</a>) got a boost, surging 33% to $3.1749 after the company reported better-than-expected first-quarter sales results.</li>
<li>Lobo EV Technologies Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LOBO#NASDAQ">LOBO</a>) shares were also up, gaining 116% to $1.6001 after the company issued a year-over-year increase in its FY25 revenue guidance.</li>
</ul>
Equities Trading DOWN
<ul class="wp-block-list">
<li>Xenon Pharmaceuticals Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XENE#NASDAQ">XENE</a>) shares dropped 17% to $29.90 following first-quarter financial results.</li>
<li>Shares of Affimed N.V. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AFMD#NASDAQ">AFMD</a>) were down 81% to $0.1345 after Leerink Partners downgraded the stock from Outperform to Market Perform and cut its price target from $5 to $0.39.</li>
<li>Halozyme Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HALO#NASDAQ">HALO</a>) was down, falling 26% to $49.26. Leerink Partners downgraded Halozyme Therapeutics from Market Perform to Underperform and announced a $47 price target.</li>
</ul>
Commodities In commodity news, oil traded up 2.9% to $63.75 while gold traded up 0.8% at $3,253.80.
Silver traded up 1.6% to $33.130 on Tuesday, while copper rose 2.1% to $4.7180.
Euro zone
European shares were mostly higher today. The eurozone's STOXX 600 gained 0.12%, while Spain's IBEX 35 Index rose 0.83%. London's FTSE 100 fell 0.02%, Germany's DAX 40 gained 0.31% and France's CAC 40 gained 0.30% during the session.
Asia Pacific Markets
Asian markets closed mostly higher on Tuesday, with Japan's Nikkei gaining 1.43%, Hong Kong's Hang Seng Index dipping 1.87%, China's Shanghai Composite Index gaining 0.17% and India's BSE Sensex falling 1.55%.
Economics
The annual inflation rate in the US slowed to 2.3% in April from 2.4% in the previous month and versus market estimates of 2.4%.
Now Read This: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/25/05/45347296/this-target-analyst-turns-bearish-here-are-top-5-downgrades-for-monday">This Target Analyst Turns Bearish; Here Are Top 5 Downgrades For Monday</a> </li>
</ul>
Photo via Shutterstock

HALO

HCWB

LOBO

MVST

XENE

Crude Oil Gains 3%; US Inflation Eases In April

U.S. stocks traded mixed this morning, with the Nasdaq Composite gaining around 250 points on Tuesday.
The Dow traded down 0.20% to 42,323.48 while the NASDAQ gained 1.34% to 18,958.85. The S&amp;P 500 also rose, gaining, 0.76% to 5,888.84.
Check This Out: <a href="https://www.benzinga.com/25/05/45373483/top-2-materials-stocks-that-may-keep-you-up-at-night-in-may">Top 2 Materials Stocks That May Keep You Up At Night In May</a>
Leading and Lagging Sectors Information technology shares jumped by 1.6% on Tuesday.
In trading on Tuesday, health care stocks fell by 2%.
Top Headline
Under Armour (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UAA#NYSE">UAA</a>) reported better-than-expected sales for its fourth quarter on Tuesday.
The company posted quarterly losses of 8 cents per share which met the analyst consensus estimate. The company reported quarterly sales of $1.18 billion which beat the analyst consensus estimate of $1.16 billion.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul class="wp-block-list">
<li>HCW Biologics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HCWB#NASDAQ">HCWB</a>) shares shot up 159% to $13.72 after the company announced it presented studies on HCW9206.</li>
<li>Shares of iCoreConnect Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICCT#NASDAQ">ICCT</a>) got a boost, surging 174% to $4.00.</li>
<li>Lobo EV Technologies Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LOBO#NASDAQ">LOBO</a>) shares were also up, gaining 124% to $1.6492 after the company issued a year-over-year increase in its FY25 revenue guidance.</li>
</ul>
Equities Trading DOWN
<ul class="wp-block-list">
<li>Polyrizon Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLRZ#NASDAQ">PLRZ</a>) shares dropped 90% to $0.0330. Polyrizon launched preclinical studies for intranasal benzodiazepines targeting $3.15 billion acute seizure market.</li>
<li>Shares of Affimed N.V. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AFMD#NASDAQ">AFMD</a>) were down 80% to $0.1401 after Leerink Partners downgraded the stock from Outperform to Market Perform and cut its price target from $5 to $0.39.</li>
<li>DevvStream Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DEVS#NASDAQ">DEVS</a>) was down, falling 59% to $0.5308.</li>
</ul>
Commodities In commodity news, oil traded up 1.8% to $63.04 while gold traded up 0.3% at $3,238.90.
Silver traded up 0.6% to $32.825 on Tuesday, while copper rose 1.4% to $4.6860.
Euro zone
European shares were mostly higher today. The eurozone's STOXX 600 gained 0.1%, while Spain's IBEX 35 Index rose 0.9%. London's FTSE 100 fell 0.1%, Germany's DAX 40 gained 0.2% and France's CAC 40 gained 0.2% during the session.
Asia Pacific Markets
Asian markets closed mostly higher on Tuesday, with Japan's Nikkei gaining 1.43%, Hong Kong's Hang Seng Index dipping 1.87%, China's Shanghai Composite Index gaining 0.17% and India's BSE Sensex falling 1.55%.
Economics
The annual inflation rate in the US slowed to 2.3% in April from 2.4% in the previous month and versus market estimates of 2.4%.
Now Read This: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/25/05/45347296/this-target-analyst-turns-bearish-here-are-top-5-downgrades-for-monday">This Target Analyst Turns Bearish; Here Are Top 5 Downgrades For Monday</a> </li>
</ul>
Photo via Shutterstock

DEVS

ICCT

PLRZ

Nasdaq Rises Over 1%; Under Armour Posts Strong Q4 Sales

Trading Halt: Halt status updated at 8:50:00 AM ET: Quotation Resumption: News and Resumption Times

Affirmed N.V. shares are trading lower after Leerink Partners downgraded the stock from Outperform to Market Perform and cut its price target from $5 to $0.39.

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul class="wp-block-list">
<li>Barclays analyst Julian Mitchell upgraded the rating for Stanley Black &amp; Decker, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SWK#NYSE">SWK</a>) from Equal-Weight to Overweight and raised the price target from $69 to $90. Stanley Black &amp; Decker shares closed at $72.53 on Monday. <a href="https://www.benzinga.com/quote/swk/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>UBS analyst Manav Gupta upgraded PBF Energy Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PBF#NYSE">PBF</a>) from Neutral to Buy and boosted the price target from $20 to $26. PBF Energy shares closed at $20.79 on Monday. <a href="https://www.benzinga.com/quote/pbf/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Baird analyst Mircea Dobre upgraded Terex Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TEX#NYSE">TEX</a>) from Neutral to Outperform and raised the price target from $48 to $66. Terex shares closed at $44.79 on Monday. <a href="https://www.benzinga.com/quote/AFRM/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Baird analyst Mircea Dobre upgraded the rating for Caterpillar Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAT#NYSE">CAT</a>) from Neutral to Outperform and boosted the price target from $309 to $395. Caterpillar shares closed at $342.55 on Monday. <a href="https://www.benzinga.com/quote/AFRM/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Baird analyst Joel Beatty upgraded argenx SE (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARGX#NASDAQ">ARGX</a>) from Neutral to Outperform and maintained the price target of $680. argenx shares closed at $560.90 on Monday. <a href="https://www.benzinga.com/quote/MSFT/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying CAT stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="565" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/13084658/image-143-1024x565.png" alt="" class="wp-image-913435" style="width:600px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/13084658/image-143-1024x565.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/13084658/image-143-300x165.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/13084658/image-143-768x424.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/13084658/image-143.png 1137w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/earnings/25/05/45368490/under-armour-cyberark-software-and-3-stocks-to-watch-heading-into-tuesday">Under Armour, CyberArk Software And 3 Stocks To Watch Heading Into Tuesday</a> </li>
</ul>
Photo via Shutterstock

Upgrades

ARGX

NXRT

This Caterpillar Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday

Trading Halt: Halted at 8:25:00 a.m. ET - Trading Halt: Halt News Pending

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul class="wp-block-list">
<li>Compass Point analyst Merrill Ross downgraded the rating for Independence Realty Trust, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IRT#NYSE">IRT</a>) from Buy to Neutral and announced a $22 price target. Independence Realty Trust shares closed at $19.31 on Monday. <a href="https://www.benzinga.com/quote/IRT/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>DA Davidson analyst Rudy Kessinger downgraded the rating for Rapid7, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RPD#NASDAQ">RPD</a>) from Neutral to Underperform and lowered the price target from $29 to $21. Rapid7 shares closed at $26.74 on Monday. <a href="https://www.benzinga.com/quote/RPD/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Compass Point analyst Merrill Ross downgraded NexPoint Residential Trust, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NXRT#NYSE">NXRT</a>) from Buy to Neutral and slashed the price target from $50 to $42.5. NexPoint Residential shares closed at $37.53 on Monday. <a href="https://www.benzinga.com/quote/NXRT/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Leerink Partners analyst Daina Graybosch downgraded Affimed N.V. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AFMD#NASDAQ">AFMD</a>) from Outperform to Market Perform and cut the price target from $5 to $0.39. Affimed shares closed at $0.6930 on Monday. <a href="https://www.benzinga.com/quote/AFMD/analyst-ratings">See how other analysts view this stock</a>.</li>
</ul>
Considering buying RPD stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="576" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/13075757/image-142-1024x576.png" alt="" class="wp-image-913351" style="width:633px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/13075757/image-142-1024x576.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/13075757/image-142-300x169.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/13075757/image-142-768x432.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/13075757/image-142.png 1095w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/earnings/25/05/45368490/under-armour-cyberark-software-and-3-stocks-to-watch-heading-into-tuesday">Under Armour, CyberArk Software And 3 Stocks To Watch Heading Into Tuesday</a> </li>
</ul>
Photo via Shutterstock

Pre-Market Outlook

This Rapid7 Analyst Turns Bearish; Here Are Top 4 Downgrades For Tuesday

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul class="wp-block-list">
<li>Piper Sandler raised ZoomInfo Technologies Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZI#NASDAQ">ZI</a>) price target from $9 to $11. Piper Sandler analyst Brent Bracelin maintained a Neutral rating. ZoomInfo shares closed at $10.31 on Monday. <a href="https://www.benzinga.com/quote/ZI/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Needham cut the price target for Annexon, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANNX#NASDAQ">ANNX</a>) from $16 to $11. Needham analyst Joseph Stringer maintained a Buy rating. Annexon shares closed at $1.77 on Monday. <a href="https://www.benzinga.com/quote/ANNX/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Compass Point slashed NexPoint Residential Trust, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NXRT#NYSE">NXRT</a>) price target from $50 to $42.5. Compass Point analyst Merrill Ross downgraded the stock from Buy to Neutral. NexPoint Residential Trust shares closed at $37.53 on Monday. <a href="https://www.benzinga.com/quote/NXRT/analyst-ratings">See how other analysts view this stock.</a></li>
<li>DA Davidson lowered the price target for Rapid7, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RPD#NASDAQ">RPD</a>) from $29 to $21. DA Davidson analyst Rudy Kessinger downgraded the stock from Neutral to Underperform. Rapid7 shares closed at $26.74 on Monday. <a href="https://www.benzinga.com/quote/RPD/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Benchmark slashed the price target for indie Semiconductor, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INDI#NASDAQ">INDI</a>) from $8 to $6. Benchmark analyst Cody Acree maintained a Buy rating. indie Semiconductor shares closed at $2.64 on Monday. <a href="https://www.benzinga.com/quote/INDI/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Leerink Partners cut Affimed N.V. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AFMD#NASDAQ">AFMD</a>) price target from $5 to $0.39. Leerink Partners analyst Daina Graybosch downgraded the stock from Outperform to Market Perform. Affimed shares settled at $0.6930 on Monday. <a href="https://www.benzinga.com/quote/AFMD/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Barclays increased Stanley Black &amp; Decker, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SWK#NYSE">SWK</a>) price target from $69 to $90. Barclays analyst Julian Mitchell upgraded the stock from Equal-Weight to Overweight. Stanley Black &amp; Decker shares closed at $72.53 on Monday. <a href="https://www.benzinga.com/quote/SWK/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Canaccord Genuity cut BILL Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BILL#NYSE">BILL</a>) price target from $105 to $75. Canaccord Genuity analyst Joseph Vafi maintained a Buy rating. BILL Holdings shares closed at $47.37 on Monday.  <a href="https://www.benzinga.com/quote/BILL/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Jefferies increased the price target for Matson, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MATX#NYSE">MATX</a>) from $125 to $135. Jefferies analyst Omar Nokta maintained a Buy rating. Matson shares settled at $113.94 on Monday. <a href="https://www.benzinga.com/quote/MATX/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>HC Wainwright &amp; Co. slashed Neurogene Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NGNE#NASDAQ">NGNE</a>) price target from $50 to $45. HC Wainwright &amp; Co. analyst Mitchell Kapoor maintained a Buy rating. Neurogene shares closed at $17.70 on Monday. <a href="https://www.benzinga.com/quote/NGNE/analyst-ratings">See how other analysts view this stock</a>.</li>
</ul>
Considering buying SWK stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="586" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/13075100/image-141-1024x586.png" alt="" class="wp-image-913331" style="width:553px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/13075100/image-141-1024x586.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/13075100/image-141-300x172.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/13075100/image-141-768x439.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/13075100/image-141.png 1128w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/earnings/25/05/45368490/under-armour-cyberark-software-and-3-stocks-to-watch-heading-into-tuesday">Under Armour, CyberArk Software And 3 Stocks To Watch Heading Into Tuesday</a> </li>
</ul>
Photo via Shutterstock

ANNX

BILL

INDI

MATX

NGNE

Stanley Black & Decker To Rally Around 24%? Here Are 10 Top Analyst Forecasts For Tuesday

Leerink Partners analyst Daina Graybosch downgrades Affimed (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AFMD#NASDAQ">AFMD</a>) from Outperform to Market Perform and lowers the price target from $5 to $0.39.

Leerink Partners Downgrades Affimed to Market Perform, Lowers Price Target to $0.39

Biotech

General

Affimed Demonstrates Increased AFM24 Exposure Correlates With Improved Response Rates And Progression-Free Survival In Refractory NSCLC Patients At AACR Annual Meeting

MANNHEIM, Germany, April 23, 2025 (GLOBE NEWSWIRE) -- Affimed N.V. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AFMD#NASDAQ">AFMD</a>) ("Affimed", or the "Company"), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced an abstract on the phase 2 LuminICE-203 study of its innate cell engager (ICE&#xAE;) acimtamig in combination with AlloNK&#xAE; (AB-101) has been accepted for an oral presentation at the Annual Meeting of the American Society for Clinical Oncology (ASCO) taking place May 30 – June 3, 2025 in Chicago, Illinois. In addition, two abstracts on AFM24 in combination with atezolizumab in non-small cell lung cancer (NSCLC) have been accepted as poster presentations.

Affimed Says Abstract On Phase 2 LuminICE-203 Study Of ICE Acimtamig In Combination With AB-101 Accepted For Oral Presentation At ASCO 2025

Affimed N.V. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AFMD#NASDAQ">AFMD</a>), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today that it has received a written notice (the "Notice"), dated April 15, 2025, from the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") indicating that, for the last thirty (30) consecutive business days, the bid price for the Company's common shares had closed below the minimum $1.00 per share requirement for continued listing on the Nasdaq under Nasdaq Listing Rule 5450(a)(1) (the "Minimum Bid Price Rule").
In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company has been provided an initial period of 180 calendar days, or until October 13, 2025, to regain compliance. If the Company fails to regain compliance with the Minimum Bid Price Rule during this period, the Company may consider applying to transfer its securities from The Nasdaq Global Select Market to The Nasdaq Capital Market, provided that the Company meets the applicable market value of publicly held shares required for continued listing and all other applicable requirements for initial listing on The Nasdaq Capital Market (except for the bid price requirement). Such transfer would provide the Company with an additional 180 calendar days, or until April 13, 2025, to regain compliance. There can be no assurance that the Company would be eligible for the additional 180 calendar day compliance period, if applicable, or that the Nasdaq staff would grant the Company's request for continued listing.
The Notice has no immediate effect on the listing or trading of the Company's common shares.
The Company intends to monitor the bid price of its common shares and consider available options to regain compliance with the Minimum Bid Price Rule.

Government

Regulations

Affimed Receives Nasdaq Notice Over Low Share Price, Has Until October to Regain Compliance

Affimed shares are trading lower. The company reported findings from a post-hoc exposure-response analysis in patients treated with 480 mg AFM24.

Affimed N.V. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AFMD#NASDAQ">AFMD</a>) ("Affimed," or the "Company"), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced updated clinical data from the ongoing AFM24-102 trial of AFM24/atezolizumab combination therapy in heavily pretreated NSCLC patients. Results continue to demonstrate meaningful clinical activity in both NSCLC EGFRwt and EGFRmut patients with good tolerability. In addition, the Company reported findings from a post-hoc exposure-response analysis in patients treated with 480 mg AFM24 showing higher AFM24 exposure is associated with significantly better response rates, improved PFS and overall survival (OS). Based on these data, the future development program for AFM24 will use a dose of 720 mg weekly, a dose that has already been successfully tested in the phase 1 study of AFM24 showing a manageable safety profile.

Affimed Reports Results for Cancer Therapy in NSCLC Patients

Press Releases

Affimed to Host Investor Conference Call Highlighting Clinical Data from AFM24 in Combination with Atezolizumab in Non-Small Cell Lung Cancer

Affimed Reports Promising Phase 1 Efficacy and Safety Data for AFM28 in Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)

Health Care

Affimed Reports Positive Clinical Update on AFM24/Atezolizumab Combination Therapy in Non-Small Cell Lung Cancer (NSCLC)

Affimed to Present at the Leerink Partners Global Healthcare Conference 2025

Affimed Announces Acceptance of AFM24 Abstract on Dose Optimization for Presentation at American Association for Cancer Research Annual Meeting

Affimed Announces Receipt of NASDAQ Deficiency Notice Regarding Minimum Bid Price Requirement

Affimed Announces Acceptance of Three Abstracts for Presentation at the American Society for Clinical Oncology Annual Meeting

Affimed Shows Higher Exposure of AFM24 is Associated with Significantly Higher Response Rates and Progression-Free Survival in Refractory NSCLC Patients at AACR Annual Meeting

Comments

Affimed

뉴스

파트너 / 기고자

벤징가 글로벌